Paragon, UBM team up on stem cell partnership

CMO Paragon Bioservices has teamed with The University of Maryland Baltimore to form a public-private partnership to develop and manufacture stem cell therapies. "The main objective of the consortium is to accelerate the development of novel strategies for regenerative medicine, including new treatments and preventatives derived from stem cell research," explained Dr. Curt Civin, director of the University of Maryland's Center for Stem Cell Biology and Regenerative Medicine, in a statement. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.